Journal article 506 views 128 downloads
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
Lawrence A. Leiter,
Steve Bain 
,
Deepak L. Bhatt,
John B. Buse,
C. David Mazer,
Richard E. Pratley,
Søren Rasmussen,
Maria Sejersten Ripa,
Hrvoje Vrazic,
Subodh Verma
,
Deepak L. Bhatt,
John B. Buse,
C. David Mazer,
Richard E. Pratley,
Søren Rasmussen,
Maria Sejersten Ripa,
Hrvoje Vrazic,
Subodh Verma
Diabetes, Obesity and Metabolism
Swansea University Author:
Steve Bain
-
PDF | Version of Record
Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC).
Download (728.43KB)
DOI (Published version): 10.1111/dom.14079
Abstract
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
| Published in: | Diabetes, Obesity and Metabolism |
|---|---|
| ISSN: | 1462-8902 1463-1326 |
| Published: |
Wiley
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa54314 |
| Keywords: |
blood pressure, cardiovascular, liraglutide, MACE, semaglutide |
|---|---|
| College: |
Faculty of Medicine, Health and Life Sciences |